Author

Shirat Nakabiri

Observed name: Shirati Nakabiri

OpenAlex ID: A5133083373

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

2026 · Diana Anena, Elizabeth Chappell, et al. · Contemporary Clinical Trials · 2

Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial

2026 · Mutsa Bwakura-Dangarembizi, Elizabeth Chappell, et al. · The Lancet

Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial

2026 · Anne E M Kamphuis, Anne E M Kamphuis, et al. · The Lancet HIV

Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial

2026 · Adeodata R Kekitiinwa, Angus Jennings, et al. · The Lancet HIV

Works count: 4

Citation count: 2

H-index: 1

I10-index: